A functional study on prostanoid receptors involved in cultured human iridal melanocyte stimulation.
The effects of various prostanoids on the growth, melanogenesis and dendrification of cultured iridal melanocytes were studied. Iridal melanocytes were isolated and cultured with medium supplemented with cAMP elevating agents and basic fibroblast growth factor (bFGF) (complete medium). The iridal melanocytes were plated into multiple well plates and cultured with complete medium or various deleted media with or without various prostanoids at different concentrations. After 6 days, the numbers of cells and dendrites were counted and melanin content was measured and compared with controls. Prostaglandin E(2), an EP(2)receptor agonist (AH 13205) and AGN 192093 (thromboxane mimetic) stimulated growth, melanogenesis and dendrification of cultured iridal melanocytes in cAMP-deleted medium. A mixed EP(1)and EP(3)receptor agonist (sulprostone), a EP(4)receptor agonist (ONO-AE1-329), IP receptor agonists (cicaprost or iloprost) and a TP receptor agonist (U-46619) showed no effect. Prostaglandin D(2)showed stimulating effects. However, these stimulating effects could not be blocked by the addition of a DP receptor antagonist (BW A868C). Furthermore, a DP receptor agonist (BW 245C) showed no effects, indicating that the effect of prostaglandin D(2)may involve receptors other than the DP receptor subtype. The present study indicates that: (1) among various EP receptor agonists, only an EP(2)receptor agonist has stimulating effects on iridal melanocytes; (2) DP, IP and TP receptor agonists do not have stimulating effects; and (3) the mechanisms of action of prostaglandin D(2)and AGN 192093 need further study.
Hu
D N
DN
Tissue Culture Center, Department of Pathology & Laboratory Medicine, The New York Eye and Ear Infirmary, 310 E. 14th Street, New York, NY 10003, U.S.A. dhu@nyee.edu
McCormick
S A
SA
Woodward
D F
DF
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000328:Adult; D002452:Cell Count; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000502:physiology; D015232:Dinoprostone / Q000031:analogs & derivatives* / Q000494:pharmacology; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000502:physiology; D006801:Humans; D006827:Hydantoins / Q000494:pharmacology; D007498:Iris / Q000166:cytology*; D008543:Melanins / Q000032:analysis; D008544:Melanocytes / Q000502:physiology*; D011448:Prostaglandin Antagonists / Q000502:physiology; D011466:Prostanoic Acids / Q000494:pharmacology; D011982:Receptors, Prostaglandin / Q000819:agonists / Q000502:physiology*
D006827:Hydantoins; D008543:Melanins; D011448:Prostaglandin Antagonists; D011466:Prostanoic Acids; D011982:Receptors, Prostaglandin; D016222:Fibroblast Growth Factor 2; C058848:BW A868C; C081039:AH 13205; C016767:sulprostone; C030669:BW 245C; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D011464:Epoprostenol; D000242:Cyclic AMP; D015232:Dinoprostone; C043867:cicaprost